Prosecution Insights
Last updated: April 19, 2026
Application No. 18/656,006

Core biopsy tissue sample dislodging onto an adhesives-free strip on an insert fitting into industry-standard cassette for further processing

Final Rejection §103
Filed
May 06, 2024
Examiner
TOWA, RENE T
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
URO-1, Inc.
OA Round
4 (Final)
49%
Grant Probability
Moderate
5-6
OA Rounds
4y 3m
To Grant
66%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allow Rate
370 granted / 760 resolved
-21.3% vs TC avg
Strong +17% interview lift
Without
With
+17.0%
Interview Lift
resolved cases with interview
Typical timeline
4y 3m
Avg Prosecution
51 currently pending
Career history
811
Total Applications
across all art units

Statute-Specific Performance

§101
6.7%
-33.3% vs TC avg
§103
49.6%
+9.6% vs TC avg
§102
14.7%
-25.3% vs TC avg
§112
23.4%
-16.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 760 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This Office action is responsive to an amendment filed June 30, 2025. Claims 11-17 & 28 are pending. Claims 1-10 & 18-27 have been canceled. New claim 28 has been added. Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim(s) 12 & 15-16 & 28 is/are rejected under 35 U.S.C. 103 as being unpatentable over Pasternak et al. (US 2014/0377148) (“Pasternak” hereinafter) in view of Jorulf (WO 93/20753), Jarial (US 2012/0022397) further in view of McGhie (US 2013/0102925). In regards to claim 28, Pasternak discloses a core biopsy tissue sample processing system comprising: a core biopsy needle 10 that has a distal portion with a cradle 18 comprising an axially extending floor, wherein said cradle 18 is configured to hold a tissue sample that has an exposed axially extending side of the entire length of the tissue sample facing up; and PNG media_image1.png 684 492 media_image1.png Greyscale an insert (i.e., cassette 140, 260, 360, 400) comprising a strip platform (shown at PNG media_image2.png 328 468 media_image2.png Greyscale least at figs. 5, 11A, 14A, 15A), a strip (146, 300, 412) of a material thereon configured to dislodge a tissue sample radially outward from said cradle 18 by lightly touching the exposed axially extending side of the tissue sample in a touch-and-go freehand motion in a direction approximately normal to the cradle floor and without a need for an adhesive or a special liquid attracting the sample to the strip (i.e., the Office notes that the biopsy needle and insert of Pasternak is fully capable of being used as claimed since the claimed touch-and-go action is a mere intended use limitation rather than a structural limitation of the claimed system) (see at least par 0024-0025, 0106-0108, 0152-0155, 0160-0162 & 0167-0172). Pasternak discloses a core biopsy tissue sample processing system, that fails to explicitly teach a system comprising a core biopsy needle that has a central axis and a distal portion that has a cradle with an axially extending floor that is below the central axis and a row of teeth extending up from each lateral side of the cradle floor to a level approximating that of the central axis, without overhanging the floor and with the teeth of each row spaced axially from each other by inter- tooth axial spaces, wherein said cradle is configured to hold a tissue sample between the rows of teeth with an exposed top of the tissue sample extending up above the central axis; wherein the teeth are configured to protect the tissue sample below a top of the teeth from direct compression damage. However, Jorulf teaches that it is known to provide a system comprising a core PNG media_image3.png 528 690 media_image3.png Greyscale biopsy needle 10 that has a central axis and a distal portion that has a cradle 16 with an axially extending floor that is below the central axis (see at least abstract, figs. 1-4, pg. 9, lines 4-9 and pg. 10, lines 3-12). Therefore, it would have been obvious to one of ordinary skill in the art at the time Applicant’s invention was filed to provide the biopsy needle of Pasternak comprising a core biopsy needle that has a central axis and a distal portion that has a cradle with an axially extending floor that is below the central axis as taught by Jorulf since such a modification would amount to applying a known technique (i.e., the depth of the cradle as taught by Jorulf) to a known device (i.e., as taught by Pasternak) ready for improvement to achieve a predictable result of receiving a tissue sample therein using such well-known and understood notches in the art of biopsy needles (see at least pg. 10, lines 3-12 of Jorulf)--See KSR, 550 U.S. at___, 82 USPQ2d at 1396 (See MPEP § 214 3 for a discussion of the rationale(s) listed above. See also MPEP § 2144 - §2144.09 for additional guidance regarding support for obviousness determinations). Pasternak as modified by Jorulf discloses a core biopsy tissue sample processing system, that fails to explicitly teach a system comprising a core biopsy needle that has a row of teeth extending up from each lateral side of the cradle floor to a level approximating that of the central axis, without overhanging the floor, wherein said cradle is configured to hold a tissue sample between the rows of teeth with an exposed top of the tissue sample extending up above the central axis; wherein the teeth are configured to protect the tissue sample below a top of the teeth from direct compression damage. However, Jarial teaches that it is known to provide a system comprising a core biopsy needle that has a row of teeth 47 extending up from each lateral side of the cradle floor (26, 28) to a level approximating that of the central axis, without overhanging the floor, wherein said cradle (26, 28) is configured to hold a tissue sample between the rows of teeth 47 with an exposed top of the tissue sample extending up above the central axis; wherein the teeth 47 are configured to protect the tissue sample below a top of the teeth 47 from direct compression damage (see at least fig. 11 and par 0033-0034). Therefore, it would have been obvious to one of ordinary skill in the art at the time Applicant’s invention was filed to provide the system of Pasternak as modified by Jorulf comprising a core biopsy needle that has a row of teeth extending up from each lateral side of the cradle floor to a level approximating that of the central axis, without overhanging the floor, wherein said cradle is configured to hold a tissue sample between the rows of teeth with an exposed top of the tissue sample extending up above the central axis; wherein the teeth are configured to protect the tissue sample below a top of the teeth from direct compression damage as taught by Jarial since such a modification would amount to applying a known technique (i.e., the plurality of teeth along the sides of the stylet notch as taught by Jarial) to a known device (i.e., the biopsy needle as taught by Pasternak) ready for improvement to achieve a predictable result such as improving cutting performance and preventing severed tissue cores from being compacted when the cannula is retracted so the clinician can visibly observe the true length and physical quality of the cores upon retrieval (see at least par 0033 of Jarial)--See KSR, 550 U.S. at___, 82 USPQ2d at 1396 (See MPEP § 214 3 for a discussion of the rationale(s) listed above. See also MPEP § 2144 - §2144.09 for additional guidance regarding support for obviousness determinations). Pasternak as modified by Jorulf and Jarial discloses a core biopsy tissue sample processing system, that fails to explicitly teach a system comprising a core biopsy needle with the teeth of each row spaced axially from each other by inter- tooth axial spaces. However, McGhie teaches that it is known to provide a system comprising a core biopsy needle with the teeth 504a of each row spaced axially from each other by inter- tooth axial spaces (see at least fig. 5 and par 0039-0042). Therefore, it would have been obvious to one of ordinary skill in the art at the time Applicant’s invention was filed to provide the system of Pasternak as modified by Jorulf and Jarial with the teeth of each row spaced axially from each other by inter- tooth axial spaces as taught by McGhie since such a modification would amount to applying a known technique (i.e., the inter-tooth axial spaces between the plurality of teeth as taught by McGhie) to a known device (i.e., the biopsy needle as taught by Pasternak) ready for improvement to achieve a predictable result of gripping tissue as the outer cannula is thrown over the stylet (see at least part 0040 of McGhie) even with spaces between the plurality of projections/ridges (see at least par 0040 of McGhie)--See KSR, 550 U.S. at___, 82 USPQ2d at 1396 (See MPEP § 214 3 for a discussion of the rationale(s) listed above. See also MPEP § 2144 - §2144.09 for additional guidance regarding support for obviousness determinations). In regards to claim 12, Pasternak discloses the core biopsy tissue sample processing system of claim 28, in which said strip (146, 300, 412) comprises fibrous cellulose paper (i.e., such as a mesh film of cellulose esters such as Immobilon-NC Transfer Membrane by Millipore) that is configured to dislodge said tissue sample without adhesives in said freehand, touch-and-go motion (see at least par 0107). In regards to claim 15, Pasternak discloses the core biopsy tissue sample processing system of claim 28, in which said insert (i.e., cassette 140) includes channels (i.e., spaces between cassette base 142 and cassette cover 144 as shown in fig. 6C) at sides of said strip platform that are open to each other and into which sides of said strip slide (see at least figs. 5 & 6B-C). In regards to claim 16, Pasternak discloses the core biopsy tissue sample processing system of claim 28, in which said insert (i.e., cassette 140, 260, 360, 400) includes surface features (150, 152, 310, 312) configured to retain said strip (146, 300, 412) in place over said platform (shown at least at figs. 5, 11A, 14A & 15A) (see at least par 0102, 0148 & 0151). Claim(s) 11 & 14 is/are rejected under 35 U.S.C. 103 as being unpatentable over Pasternak (‘148) in view of Jorulf (‘753), Jarial (‘397), McGhie (‘925) further in view of Morton et al. (US 2002/0183719) (“Morton” hereinafter). In regards to claim 11, Pasternak as modified by Jorulf, Jarial and McGhie discloses the core biopsy tissue sample processing system of claim 28, that fails to explicitly teach a system in which said strip comprises Nylon 66 that is electrostatically positively charged sufficiently to dislodge said tissue sample without adhesives in said freehand, touch-and-go motion. However, Morton teaches that it is known to provide a system in which said strip comprises Nylon 66 that is electrostatically positively charged sufficiently to dislodge said tissue sample without adhesives (see at least fig. 4 and par 0061 & 0066-0070). Therefore, it would have been obvious to one of ordinary skill in the art at the time Applicant’s invention was filed to provide the system of Pasternak as modified by Jorulf, Jarial and McGhie in which said strip comprises Nylon 66 that is electrostatically positively charged sufficiently to dislodge said tissue sample without adhesives, as taught by Morton, in said freehand, touch-and-go motion as taught by Pasternak since such a modification would amount to a simple substitution of one known element (i.e., as taught by Morton) for another (i.e., as taught by Pasternak) to obtain predictable results such as providing porous or absorptive materials, which may be modified for chemical binding or adsorption properties to facilitate collecting cellular and cellular component samples for cytological exam (see at least par 0061 & 0066 of Morton)--See KSR, 550 U.S. at___, 82 USPQ2d at 1396 (See MPEP § 214 3 for a discussion of the rationale(s) listed above. See also MPEP § 2144 - §2144.09 for additional guidance regarding support for obviousness determinations). In regards to claim 14, Pasternak as modified by Jorulf, Jarial and McGhie discloses the core biopsy tissue sample processing system of claim 11, that fails to explicitly teach a system in which said strip comprises a polyamide that is electrostatically positively charged sufficiently to dislodge said tissue sample from said cradle 18 by said freehand, touch-and-go motion. However, Morton teaches that it is known to provide a system in which said strip comprises a polyamide (i.e., nylon 66) that is electrostatically positively charged sufficiently to dislodge said tissue sample (see at least fig. 4 and par 0061 & 0066-0070). Therefore, it would have been obvious to one of ordinary skill in the art at the time Applicant’s invention was filed to provide the system of Pasternak as modified by Smith in which said strip comprises a polyamide that is electrostatically positively charged sufficiently to dislodge said tissue sample, as taught by Morton, from said cradle by said freehand, touch-and-go motion as taught by Pasternak since such a modification would amount to a simple substitution of one known element (i.e., as taught by Morton) for another (i.e., as taught by Pasternak) to obtain predictable results such as providing porous or absorptive materials, which may be modified for chemical binding or adsorption properties to facilitate collecting cellular and cellular component samples for cytological exam (see at least par 0061 & 0066 of Morton)--See KSR, 550 U.S. at___, 82 USPQ2d at 1396 (See MPEP § 214 3 for a discussion of the rationale(s) listed above. See also MPEP § 2144 - §2144.09 for additional guidance regarding support for obviousness determinations). Claim(s) 13 is/are rejected under 35 U.S.C. 103 as being unpatentable over Pasternak (‘148) in view of Jorulf (‘753), Jarial (‘397), McGhie (‘925) further in view of Sikes et al. (US 2019/0113512) (“Sikes” hereinafter). Pasternak as modified by Jorulf, Jarial and McGhie discloses the core biopsy tissue sample processing system of claim 28, that fails to explicitly teach a system in which said strip comprises Cellulose Chromatography Paper that is configured to dislodge said tissue sample without adhesives in said freehand, touch-and-go motion. However, Sikes teaches that it is known to provide a system in which said strip comprises Cellulose Chromatography Paper that is configured to dislodge said tissue sample without adhesives (see at least par 0016, 0026, 0036, 0041, 0043 & 0167). Therefore, it would have been obvious to one of ordinary skill in the art at the time Applicant’s invention was filed to provide the system of Pasternak as modified by Jorulf, Jarial and McGhie in which said strip comprises Cellulose Chromatography Paper that is configured to dislodge said tissue sample without adhesives, as taught by Sikes, in said freehand, touch-and-go motion as taught by Pasternak since such a modification would amount to a simple substitution of one known element (i.e., as taught by Pasternak) for another (i.e., as taught by Sikes) to obtain predictable results such as providing a substrate-anchoring domain in a paper-based assay format permits the rapid and oriented adsorption of the antigen-binding protein (see at least par 0167 of Sikes)--See KSR, 550 U.S. at___, 82 USPQ2d at 1396 (See MPEP § 214 3 for a discussion of the rationale(s) listed above. See also MPEP § 2144 - §2144.09 for additional guidance regarding support for obviousness determinations). Claim(s) 17 is/are rejected under 35 U.S.C. 103 as being unpatentable over Pasternak (‘148) in view of Jorulf (‘753), Jarial (‘397), McGhie (‘925) further in view of Snoke et al. (US 2023/0134295) (“Snoke” hereinafter). Pasternak as modified by Jorulf, Jarial and McGhie discloses the core biopsy tissue processing system of claim 28, that fails to explicitly teach a system in which said insert is configured to fit in an industry-standard biopsy sample cassette that has an interior opening with sides 30-35 mm by 25-30 mm and 4-6 mm depth. However, Snoke teaches that it is known to provide a system in which said insert 800 is configured to fit in an industry-standard biopsy sample cassette 900 (see at least figs. 8-12B and par 0040-0042). Therefore, it would have been obvious to one of ordinary skill in the art at the time Applicant’s invention was filed to provide the system of Pasternak as modified by Jorulf, Jarial and McGhie in which said insert is configured to fit in an industry-standard biopsy sample cassette as taught by Snoke since such a modification would amount to applying a known technique (i.e., as taught by Snoke) to a known device (i.e., as taught by Pasternak) ready for improvement to achieve a predictable result such as facilitating, storage and shipment of the insert to a pathology lab (see at least par 0042 of Snoke)--See KSR, 550 U.S. at___, 82 USPQ2d at 1396 (See MPEP § 214 3 for a discussion of the rationale(s) listed above. See also MPEP § 2144 - §2144.09 for additional guidance regarding support for obviousness determinations). Pasternak as modified by Jorulf, Jarial, McGhie and Snoke discloses the core biopsy tissue processing system of claim 28, that fails to explicitly teach a system in which the industry-standard biopsy sample cassette has an interior opening with sides 30-35 mm by 25-30 mm and 4-6 mm depth. However, since Snoke teaches accommodating the insert in an industry-standard biopsy sample cassette (i.e., available from Leica Biosystems Inc. of Buffalo Grove, Ill.) (see at least par 0040), it would have been obvious to one of ordinary skill in the art at the time Applicant’s invention was filed to provide the system of Pasternak as modified by Jorulf, Jarial, McGhie and Snoke in which the industry-standard biopsy sample cassette has an interior opening with sides 30-35 mm by 25-30 mm and 4-6 mm depth as claimed in order to accommodate the insert therein. Claim(s) 17 & 28 is/are rejected under 35 U.S.C. 103 as being unpatentable over Snoke et al. (US 2023/0134295) (“Snoke” hereinafter) in view of Jorulf (WO 93/20753), Jarial (US 2012/0022397) further in view of McGhie (US 2013/0102925). In regards to claim 28, Snoke discloses a core biopsy tissue sample processing system comprising: a core biopsy needle A2 that has a distal portion with a cradle A4 comprising an PNG media_image4.png 440 526 media_image4.png Greyscale axially extending floor, wherein said cradle A4 is configured to hold a tissue sample that has an exposed side (see at least fig. 12A and par 0002); and an insert 800 comprising a strip platform 808, a strip 840 of a material thereon that is configured to dislodge a tissue sample from said cradle A4 by lightly touching the exposed side of the tissue sample in a touch-and-go freehand motion of the cradle A4 relative to the strip 840, without a need for an adhesive (see at least figs. 8-12B and par 0006-0007, 0038 & 0040-0042). Snoke discloses a core biopsy tissue sample processing system, that fails to explicitly teach a system comprising a core biopsy needle that has a central axis and a distal portion that has a cradle with an axially extending floor that is below the central axis and a row of teeth extending up from each lateral side of the cradle floor to a level approximating that of the central axis, without overhanging the floor and with the teeth of each row spaced axially from each other by inter- tooth axial spaces, wherein said cradle is configured to hold a tissue sample between the rows of teeth with an exposed top of the tissue sample extending up above the central axis; wherein the teeth are configured to protect the tissue sample below a top of the teeth from direct compression damage. However, Jorulf teaches that it is known to provide a system comprising a core PNG media_image3.png 528 690 media_image3.png Greyscale biopsy needle 10 that has a central axis and a distal portion that has a cradle 16 with an axially extending floor that is below the central axis (see at least abstract, figs. 1-4, pg. 9, lines 4-9 and pg. 10, lines 3-12). Therefore, it would have been obvious to one of ordinary skill in the art at the time Applicant’s invention was filed to provide the biopsy needle of Snoke comprising a core biopsy needle that has a central axis and a distal portion that has a cradle with an axially extending floor that is below the central axis as taught by Jorulf since such a modification would amount to applying a known technique (i.e., the depth of the cradle as taught by Jorulf) to a known device (i.e., as taught by Pasternak) ready for improvement to achieve a predictable result of receiving a tissue sample therein using such well-known and understood notches in the art of biopsy needles (see at least pg. 10, lines 3-12 of Jorulf)--See KSR, 550 U.S. at___, 82 USPQ2d at 1396 (See MPEP § 214 3 for a discussion of the rationale(s) listed above. See also MPEP § 2144 - §2144.09 for additional guidance regarding support for obviousness determinations). Snoke as modified by Jorulf discloses a core biopsy tissue sample processing system, that fails to explicitly teach a system comprising a core biopsy needle that has a row of teeth extending up from each lateral side of the cradle floor to a level approximating that of the central axis, without overhanging the floor, wherein said cradle is configured to hold a tissue sample between the rows of teeth with an exposed top of the tissue sample extending up above the central axis; wherein the teeth are configured to protect the tissue sample below a top of the teeth from direct compression damage. However, Jarial teaches that it is known to provide a system comprising a core biopsy needle that has a row of teeth 47 extending up from each lateral side of the cradle floor (26, 28) to a level approximating that of the central axis, without overhanging the floor, wherein said cradle (26, 28) is configured to hold a tissue sample between the rows of teeth 47 with an exposed top of the tissue sample extending up above the central axis; wherein the teeth 47 are configured to protect the tissue sample below a top of the teeth 47 from direct compression damage (see at least fig. 11 and par 0033-0034). Therefore, it would have been obvious to one of ordinary skill in the art at the time Applicant’s invention was filed to provide the system of Snoke as modified by Jorulf comprising a core biopsy needle that has a row of teeth extending up from each lateral side of the cradle floor to a level approximating that of the central axis, without overhanging the floor, wherein said cradle is configured to hold a tissue sample between the rows of teeth with an exposed top of the tissue sample extending up above the central axis; wherein the teeth are configured to protect the tissue sample below a top of the teeth from direct compression damage as taught by Jarial since such a modification would amount to applying a known technique (i.e., the plurality of teeth along the sides of the stylet notch as taught by Jarial) to a known device (i.e., the biopsy needle as taught by Pasternak) ready for improvement to achieve a predictable result such as improving cutting performance and preventing severed tissue cores from being compacted when the cannula is retracted so the clinician can visibly observe the true length and physical quality of the cores upon retrieval (see at least par 0033 of Jarial)--See KSR, 550 U.S. at___, 82 USPQ2d at 1396 (See MPEP § 214 3 for a discussion of the rationale(s) listed above. See also MPEP § 2144 - §2144.09 for additional guidance regarding support for obviousness determinations). Snoke as modified by Jorulf and Jarial discloses a core biopsy tissue sample processing system, that fails to explicitly teach a system comprising a core biopsy needle with the teeth of each row spaced axially from each other by inter- tooth axial spaces. However, McGhie teaches that it is known to provide a system comprising a core biopsy needle with the teeth 504a of each row spaced axially from each other by inter- tooth axial spaces (see at least fig. 5 and par 0039-0042). Therefore, it would have been obvious to one of ordinary skill in the art at the time Applicant’s invention was filed to provide the system of Snoke as modified by Jorulf and Jarial with the teeth of each row spaced axially from each other by inter- tooth axial spaces as taught by McGhie since such a modification would amount to applying a known technique (i.e., the inter-tooth axial spaces between the plurality of teeth as taught by McGhie) to a known device (i.e., the biopsy needle as taught by Snoke) ready for improvement to achieve a predictable result of gripping tissue as the outer cannula is thrown over the stylet (see at least part 0040 of McGhie) even with spaces between the plurality of projections/ridges (see at least par 0040 of McGhie)--See KSR, 550 U.S. at___, 82 USPQ2d at 1396 (See MPEP § 214 3 for a discussion of the rationale(s) listed above. See also MPEP § 2144 - §2144.09 for additional guidance regarding support for obviousness determinations). In regards to claim 17, although Snoke teaches that it is known to provide a system in which said insert 800 is configured to fit in an industry-standard biopsy sample cassette 900 (see at least figs. 8-12B and par 0040-0042), Snoke as modified by Jorulf, Jarial and McGhie discloses the core biopsy tissue processing system of claim 28, that fails to explicitly teach a system in which the industry-standard biopsy sample cassette has an interior opening with sides 30-35 mm by 25-30 mm and 4-6 mm depth. However, since Snoke teaches accommodating the insert in an industry-standard biopsy sample cassette (i.e., available from Leica Biosystems Inc. of Buffalo Grove, Ill.) (see at least par 0040), it would have been obvious to one of ordinary skill in the art at the time Applicant’s invention was filed to provide the system of Snoke as modified by Jorulf, Jarial and McGhie in which the industry-standard biopsy sample cassette has an interior opening with sides 30-35 mm by 25-30 mm and 4-6 mm depth as claimed in order to accommodate the insert therein. Response to Arguments Applicant’s arguments with respect to claim(s) 11-17 & 28 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RENE T TOWA whose telephone number is (313)446-6655. The examiner can normally be reached Mon-Fri, 9:00 AM-5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jason M. Sims can be reached on 571-272-7540. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RENE T TOWA/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

May 06, 2024
Application Filed
Oct 03, 2024
Non-Final Rejection — §103
Jan 09, 2025
Response Filed
Jan 28, 2025
Final Rejection — §103
Feb 06, 2025
Examiner Interview Summary
Feb 06, 2025
Applicant Interview (Telephonic)
Feb 06, 2025
Response after Non-Final Action
Feb 25, 2025
Request for Continued Examination
Feb 26, 2025
Response after Non-Final Action
Mar 10, 2025
Non-Final Rejection — §103
Jun 30, 2025
Response Filed
Aug 05, 2025
Applicant Interview (Telephonic)
Aug 05, 2025
Examiner Interview Summary
Nov 26, 2025
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599332
Non-Invasive Assessment Of Glymphatic Flow And Neurodegeneration From A Wearable Device
2y 5m to grant Granted Apr 14, 2026
Patent 12588861
Wearable Device And Method For Non-Invasive Assessment Of Glymphatic Flow
2y 5m to grant Granted Mar 31, 2026
Patent 12551203
Catheter with Vessel Lining for Cell Collection and Methods for Using Same
2y 5m to grant Granted Feb 17, 2026
Patent 12551731
ULTRASOUND TRANSDUCER AND SYSTEM
2y 5m to grant Granted Feb 17, 2026
Patent 12551202
BIOPSY APPARATUS HAVING A PIERCING MODULE
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
49%
Grant Probability
66%
With Interview (+17.0%)
4y 3m
Median Time to Grant
High
PTA Risk
Based on 760 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month